ArticleIn vivo (Athens, Greece)
Breast Cancer Recurrence After 46 Years of Remission: A Case Report and Clinical Implications.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimBreast cancer is the most commonly diagnosed malignancy among women worldwide. While survival outcomes have improved substantially over time, recurrence remains a significant concern, especially in estrogen receptor-positive (ER CASE REPORT: We present the case of a 96-year-old female with a history of right-sided breast cancer treated with mastectomy and adjuvant radiation therapy at age 50, who presented 46 years later with a palpable chest wall mass near her prior mastectomy scar. Imaging revealed an irregular hypoechoic lesion extending into the pectoralis muscle (BIRADS-5). Core biopsy demonstrated moderately differentiated infiltrating lobular carcinoma that was strongly ER+, progesterone receptor-negative, and HER2 non-amplified. Staging studies revealed no evidence of distant metastatic disease. Given the patient's advanced age, comorbidities, and prior radiation exposure, surgical and radiation approaches were deferred. Following multidisciplinary tumor board discussion and shared decision-making, primary endocrine therapy with tamoxifen was initiated. The patient demonstrated clinical regression within three months and tolerated therapy well.
conclusionThis case represents one of the longest reported intervals between initial remission and breast cancer recurrence, highlighting the prolonged biologic potential of dormant ER-positive tumor cells. Clinicians should maintain vigilance for recurrence even decades after treatment, particularly in hormone receptor-positive disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.